功能性消化不良与幽门螺杆菌感染的关系

功能性消化不良是临床上最常见的一种功能性胃肠病.目前,多种致病因素被认为与其有关.其中,幽门螺杆菌(Helicobacter pylori,H.pylori)感染与功能性消化不良之间的关系虽然已经得到了广泛的研究,但仍然没有得出确切一致的结论.近些年来,随着对功能性消化不良疾病认识的逐渐加深,且由于罗马标准的几经修改,较多先前的研究已经显现出自身的弊端,且各种观点相差甚远.本文旨在对功能性消化不良与H.pylori之间关系的研究及目前各方面的观点作一综述.     

幽门螺杆菌感染与功能性消化不良

功能性消化不良(FD)是指有消化不良症状,但经检查排除了引起这些症状的器质性疾病,并在过去12个月中症状至少存在12周的症征。FD根据主要症状又可分为以疼痛为主的溃疡样(ulcer like)型、以上腹饱胀不适为主的动力障碍样(dysmotility like)型以及难以归入上述二型的非特异(unsp     

幽门螺杆菌与功能性消化不良的关系

功能性消化不良（FD）曾经被命名为非溃疡性消化不良（NUD）,是指具有由胃十二指肠功能紊乱引起的症状、经检查排除引起这些症状的器质性疾病的一组临床综合征。虽然研究认为FD的发生与胃肠动力障碍、内脏高敏感性、胃酸分泌、精神心理因素和幽门螺杆菌（Hp）感染等因素有关,但目前一系列针对FD的对症治疗手段反映了FD发病机制尚不确定,     

功能性消化不良与幽门螺杆菌感染关系的探讨

功能性消化不良(Functional dyspepsid,FD)是一种常见病症,其病因与发病机理迄今尚未完全明了,幽门螺杆菌(Helicobacten pyloril,HP)的发现,无疑使这一问题更为复杂化。本文作者应用具有快速、可靠,有高度敏感的检测方法:聚合酶链反应(Polymerase chain reaction,PCR)检测336例FD患者唾液中的HP以探讨FD患者HP感染情况。     

幽门螺杆菌感染与功能性消化不良的关系探讨

2002年5月-2005年5月,我们对幽门螺杆菌（Hp）感染与功能性消化不良（FD）的关系进行了探讨。现报告如下。     

抗幽门螺杆菌感染治疗功能性消化不良

幽门螺杆菌（Ｈｅｌｉｃｏｂａｃｔｅｒｐｙｌｏｒｉ,Ｈｐ）感染与消化性溃疡及胃癌的相关已得到公认,但其与功能性消化不良（ｆｕｎｃｔｉｏｎａｌｄｙｓｐｅｐｓｉａ,ＦＤ）的关系目前尚存在争议［１］,我们拟从抗Ｈｐ治疗对ＦＤ患者症状的改善,来探讨抗Ｈｐ感染在...     

幽门螺杆菌与功能性消化不良

消化不良是指持续或反复发作的上腹痛或不适 ,包括不同程度和性质的上腹痛、上腹胀、早饱、嗳气、恶心等上腹部症状 ,病程超过 2周。功能性消化不良 (ＦＤ)是指有消化不良而经详尽的检查未能发现引起这些症状的局部或全身器质性病变[1] 。ＦＤ的病因及发病机制未明 ,目前认为是多种因素引起的临床综合征。自幽门螺杆菌 (Ｈｐ)发现以来 ,Ｈｐ与ＦＤ的关系便受到关注 ,因为ＦＤ患者中有30 %～ 6 0 %有Ｈｐ感染及由此而引起的慢性活动性胃炎。然而 ,十多年来大量的研究却一直未能为两者的关系提供明确的证据 :(1)不少调查表明 ,在ＦＤ患者中Ｈ…     

功能性消化不良与幽门螺杆菌关系的研究进展

功能性消化不良(FD)患者感染幽门螺杆菌(H.pylori)十分常见,H.pylori对于FD的发病过程有重要意义。本文旨在总结H.pylori在FD发病过程中的作用和根除H.pylori治疗对FD疾病进程影响的相关研究进展。     

幽门螺杆菌感染与功能性消化不良胃排空的关系

目的：探讨幽门螺杆菌（Ｈｐ）感染对功能性消化不良（ＦＤ）患者胃排空功能的影响。方法：１０６例ＦＤ患者，其中Ｈｐ阳性４６例，Ｈｐ阴性６０例。全部患者从胃窦粘膜取活组织做病理组织学检查并利用实时Ｂ型超声胃窦截面积法测定胃排空。结果：Ｈｐ阳性患者的空腹胃窦面积、餐后即刻胃窦面积、餐后６０分钟和１２０分钟的胃排空率（分别为０９４±１３９ｃｍ２、１３４±３１６ｃｍ２、９２３±１４０％和３５８±２３５％）与Ｈｐ阴性者（分别为１１９±２１２ｃｍ２、１２５±２７８２、９１２±１２２％和３２１％±２４０％）比较，无显著性差异（Ｐ＞００５）；活动性胃炎患者空腹胃窦面积、餐后即刻胃窦面积、餐后６０分钟和１２０分钟的排空率（分别为０７７±１４２ｃｍ２、１３２±３５ｃｍ２、１００±１２２％和３４７±２６０％）与非活动性胃炎患者（分别为１２８±２０７ｃｍ２、１２７±２５２ｃｍ２、９７４±１４５％和３３２±２４％）比较，也无显著性差异（Ｐ＞００５）。结论：Ｈｐ感染对ＦＤ患者胃排空功能无影响；与Ｈｐ感染有密切相关性的活动性胃炎也不足以引起胃排空的改变     

幽门螺杆菌与功能性消化不良

功能性消化不良(functional dyspepsia，FD)，又称为非器质性消化不良(non—organicdyspepsia，NOD)和非溃疡性消化不良(non—ul—cerdyspepsia，NUD)。本病以上腹疼痛、腹胀、易饱、暖气、烧心、恶心呕吐等上腹部不适的症状为主要临床表现，并通过内镜及实验室检查和影象学检查排除了肝、胆、脾、胰、胃及肠道的器质性病变。     

功能性消化不良患者中幽门螺杆菌感染与胃蛋白酶原水平相关性研究

目的 探讨在功能性消化不良（functional dyspepsia,FD）患者中,胃蛋白酶原（Pepsinogen,PG）水平与幽门螺杆菌（Helicobacter pylori,H.pylori）感染相关性.方法 某部新兵FD患者按H.pylori感染分成H.pylori阳性组与H.pylori阴性组,采用ELISA法对其血清PGⅠ、PGⅡ含量进行检测,血清H.pylori-IgG抗体采用定性分析法.结果 在FD患者中,H.pylori阳性组PGⅠ、PGⅡ、PGⅠ/ PGⅡ水平分别为（137.93±27.73） μg/L、（7.05±3.92） μg/L、24.69±15.5,H.pylori阴性组PGⅠ、PGⅡ、PGⅠ/ PGⅡ水平分别为（131.17±＋26.38） μg/L、（2.85±2.11） μg/L、64.0±76.44,两组相比差异均有统计学意义（tⅠ=2.714,tⅡ=17.432,tⅠ/Ⅱ=5.270,P均〈0.05）.结论 在功能性消化不良患者中,H.pylori感染可能会引起胃蛋白酶原PGⅠ、PGⅡ水平升高,以PGⅡ为主.     

Symptom-based tendencies of Helicobacter pylori eradication in patients with functional dyspepsia

AIM： To investigate whether there were symptom-based tendencies in the Helicobacter pylori （H. pylori） eradication in functional dyspepsia （FD） patients. METHODS： A randomized, single-blind, placebo-controlled study of H. pylori eradication for FD was conduct- ed. A total of 195 FD patients with H. pylori infection were divided into two groups： 98 patients in the treatment group were treated with rabeprazole 10 mg twice daily for 2 wk, amoxicillin 1.0 g and clarithromycin 0.5 g twice daily for 1 wk; 97 patients in the placebo group were given placebos as control. Symptoms of FD, such as postprandial fullness, early satiety, nausea, belching,epigastric pain and epigastric burning, were assessed 3 mo after H. pylori eradication. RESULTS： By per-protocol analysis in patients with successful H. pylori eradication, higher effective rates of 77.2% and 82% were achieved in the patients with epigastric pain and epigastric burning than those in the placebo group （P 〈 0.05）. The effective rates for postprandial fullness, early satiety, nausea and belching were 46%, 36%, 52.5% and 33.3%, respectively, and there was no significant difference from the placebo group （39.3%, 27.1%, 39.1% and 31.4%） （P 〉 0.05）. In 84 patients who received H. pylori eradication therapy, the effective rates for epigastric pain （73.8%） and epigastric burning （80.7%） were higher than those in the placebo group （P 〈 0.05）. The effective rates for postprandial fullness, early satiety, nausea and belch- ing were 41.4%, 33.3%, 50% and 31.4%, respective- ly, and did not differ from those in the placebo group （P 〉 0.05）. By intention-to-treat analysis, patients with epigastric pain and epigastric burning in the treatment group achieved higher effective rates of 60.8% and 65.7% than the placebo group （33.3% and 31.8%） （P 〈 0.05）. The effective rates for postprandial fullness, early satiety, nausea and belching were 34.8%, 27.9%, 41.1% and 26.7% respectively in the treatment group, with no significant difference from those in the placebo group （34.8%, 23.9%, 35.3% and 27.1%） （P 〉 0.05）. CONCLUSION： The efficacy of H. pylori eradication has symptom-based tendencies in FD patients. It may be effective in the subgroup of FD patients with epigastric pain syndrome.     

Prevalence of functional dyspepsia and its relationship with Helicobacter pylori infection in a Japanese population

AIM: To investigate the prevalence of functional dyspepsia and Helicobacter pylori infection and their relationship in a Japanese population. METHODS: Two thousand five hundred people who visited Shimane Institute of Health Science for their annual medical check-up from September 1998 to August 1999 were prospectively enrolled in the study. After routine medical examination, including an upper gastrointestinal study and an ultrasonographic examination, all subjects were asked standard questions to check for the presence of any symptoms that suggested dyspepsia. Helicobacter pylori infection was determined by using a serum IgG antibody concentration with an ELISA. RESULTS: Of the 2,500 persons investigated, 2,263 showed no abnormal finding in any medical examination. The presence or absence of symptoms and H. pylori infection was investigated in these 2,263 cases. Of these, 201 people (8.9%) experienced nausea, fullness and/or early satiety and were diagnosed as having dysmotility-like dyspepsia, while 118 people (5.2%) experienced pain localized to the epigastrium and were diagnosed as having ulcer-like dyspepsia. The frequency of these symptoms had a tendency to decline with age, although this was not statistically significant. In contrast, the rate of H. pylori infection increased with age. There was no significant relationship between H. pylori infection and any type of functional dyspepsia. CONCLUSIONS: Helicobacter pylori infection does not influence the prevalence of the dysmotility-like and ulcer-like dyspeptic symptoms.     

Drug treatment of functional dyspepsia

Symptomatic improvement of patients with functional dyspepsia after drug therapy is often incomplete and obtained in not more than 60% of patients. This is likely because functional dyspepsia is a heterogeneous disease. Although great advance has been achieved with the consensus definitions of the Rome I and II criteria, there are still some aspects about the definition of functional dyspepsia that require clarification. The Rome criteria explicitly recognise that epigastric pain or discomfort must be the predominant complaint in patients labelled as suffering from functional dyspepsia. However, this strict definition can create problems in the daily primary care clinical practice, where the patient with functional dyspepsia presents with multiple symptoms. Before starting drug therapy it is recommended to provide the patient with an explanation of the disease process and reassurance. A thorough physical examination and judicious use of laboratory data and endoscopy are also indicated. In general, the approach to treat patients with functional dyspepsia based on their main symptom is practical and effective. Generally, patients should be treated with acid suppressive therapy using proton-pump inhibitors if the predominant symptoms are epigastric pain or gastroesophageal reflux symptoms. Although the role of Helicobacter pylori (H pylori) in functional dyspepsia continues to be a matter of debate, recent data indicate that there is modest but clear benefit of eradication of H pylori in patients with functional dyspepsia. In addition, H pylori is a gastric carcinogen and if found it should be eliminated. Although there are no specific diets for patients with FD, it may be helpful to guide the patients on healthy exercise and eating habits.     

胃粘膜肥大细胞及其脱颗粒与Hp致病关系的探讨

目的：探讨胃粘膜肥大细胞（MC）及其脱颗粒与幽门螺杆菌（Hp）致病性的关系。方法：采用改良甲苯胺蓝染色法检测120例患者胃粘膜中MC计数及脱颗粒细胞所占比例。结果：1．Hp阳性患者胃粘膜MC计数及脱颗粒比显著高于Hp阴性患者（P＜0．01）;2．不同Hp感染胃病患者之间胃粘膜MC计数及脱颗粒比也有差异,消化性溃疡（PU）和慢性浅表性胃炎（CSG）患者胃粘膜MC计数及脱颗粒比显著高于慢性萎缩性胃炎（CAG）患者（P＜0．01）。结论：胃粘膜肥大细胞及其脱颗粒参与了Hp致病而导致胃粘膜受损。     

Role of Helicobacter pylori in functional dyspepsia

The aetiology of dyspepsia is unknown in the majority of patients. Helicobacter pylori (H pylori) is the cause in a subset of patients. A non invasive test to assess the presence of H pylori is recommended in the management of patients under the age of 50 presenting to a family practitioner with dyspepsia. A urea breath test or a stool antigen test are the most reliable non invasive tests. Eradication of H pylori will reduce the risk to the patient with dyspepsia of developing a peptic ulcer, reduce the complication rate if prescribed nonsteroid anti-inflammatory drugs and later reduce the risk of gastric cancer. The recommended treatment for non ulcer dyspepsia associated with a H pylori infection should be a 10-d course of treatment with a PPI and two antibiotics. Treatment efficacy should be assessed four weeks after completing treatment with a urea breath test or a stool antigen test.     

功能性消化不良与社会心理因素的相关性

功能性消化不良发病率居高不下,症状顽固,许多患者都伴有不同程度的焦虑抑郁情绪,严重影响了患者的生活和工作,本文就其最新的一些研究内容做一综述。